JP2023502780A5 - - Google Patents

Info

Publication number
JP2023502780A5
JP2023502780A5 JP2022530237A JP2022530237A JP2023502780A5 JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5 JP 2022530237 A JP2022530237 A JP 2022530237A JP 2022530237 A JP2022530237 A JP 2022530237A JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5
Authority
JP
Japan
Prior art keywords
agonist
item
population
til
tils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022530237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062094 external-priority patent/WO2021108455A1/en
Publication of JP2023502780A publication Critical patent/JP2023502780A/ja
Publication of JP2023502780A5 publication Critical patent/JP2023502780A5/ja
Priority to JP2025133444A priority Critical patent/JP2025159098A/ja
Withdrawn legal-status Critical Current

Links

JP2022530237A 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法 Withdrawn JP2023502780A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133444A JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940035P 2019-11-25 2019-11-25
US62/940,035 2019-11-25
US202063081539P 2020-09-22 2020-09-22
US63/081,539 2020-09-22
PCT/US2020/062094 WO2021108455A1 (en) 2019-11-25 2020-11-24 Methods for activation and expansion of tumor infiltrating lymphocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133444A Division JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Publications (2)

Publication Number Publication Date
JP2023502780A JP2023502780A (ja) 2023-01-25
JP2023502780A5 true JP2023502780A5 (https=) 2023-12-01

Family

ID=76128945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530237A Withdrawn JP2023502780A (ja) 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Country Status (8)

Country Link
US (1) US20240376428A1 (https=)
EP (1) EP4065233A4 (https=)
JP (2) JP2023502780A (https=)
KR (1) KR20220119038A (https=)
CN (1) CN115003387A (https=)
AU (1) AU2020392094A1 (https=)
CA (1) CA3162272A1 (https=)
WO (1) WO2021108455A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
EP4239059A4 (en) 2020-11-19 2024-05-15 Suzhou Grit Biotechnology Co., Ltd. METHOD FOR CULTIVATION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
CN117616115A (zh) * 2021-08-03 2024-02-27 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
US20250130220A1 (en) * 2021-09-08 2025-04-24 KSQ Therapeutics, Inc. Lymphocyte potency assay
CN118414422A (zh) * 2021-12-30 2024-07-30 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
CN118525084A (zh) * 2022-01-19 2024-08-20 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
WO2023143515A1 (zh) * 2022-01-29 2023-08-03 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
JP2025508050A (ja) * 2022-03-07 2025-03-21 ンカルタ・インコーポレイテッド Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
CN117417894A (zh) * 2023-09-15 2024-01-19 毕诺济(上海)生物技术有限公司 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
JPWO2010098429A1 (ja) * 2009-02-27 2012-09-06 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
EP3154555A4 (en) * 2014-06-10 2018-02-28 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
CN106687584B (zh) * 2014-09-04 2021-08-13 干细胞技术公司 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
RU2021118125A (ru) * 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
AU2016249005B2 (en) * 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017087784A1 (en) * 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR20200003913A (ko) * 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
CN112040987A (zh) * 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
CN112040986A (zh) * 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
CN108753718A (zh) * 2018-06-20 2018-11-06 淮安诺康生物科技有限公司 肿瘤浸润淋巴细胞til的体外扩增方法

Similar Documents

Publication Publication Date Title
JP2023502780A5 (https=)
JP2023516300A5 (https=)
US20230108584A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
EP3927370B1 (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof
TW202030323A (zh) 製備表現嵌合抗原受體的細胞之方法
JP2023502780A (ja) 腫瘍浸潤リンパ球の活性化及び増殖方法
US11957695B2 (en) Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN116656605A (zh) 用于扩增细胞群的方法、试剂盒及装置
JP2019516399A (ja) アレル編集およびその応用
US11793787B2 (en) Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2019094955A1 (en) Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
US20170020922A1 (en) Gene editing for immunological destruction of neoplasia
CN119614577A (zh) 用于细胞靶向和标记的抗cd3核酸适配体
WO2021012960A1 (zh) 一种引导PD1基因切割实现外源序列高效整合的sgRNA
Joshi et al. Activating the antitumor immune response in non‐Hodgkin lymphoma using immune checkpoint inhibitors
JP7043114B2 (ja) 細胞を活性化させるための方法およびキット
US20230181641A1 (en) Process for producing donor-batched cells expressing a recombinant receptor
US20230381313A1 (en) CD16high CD57high NK-92MI Cells
US20200317780A1 (en) METHODS FOR ENHANCING TCRab+ CELL DEPLETION
EP4262844A1 (en) Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
SG11202110164YA (en) Cd28 t cell cultures, compositions, and methods of using thereof
HK40115099A (zh) Cp16高cp57高nk-92mi细胞
RU2778411C2 (ru) Способы культивирования клеток и наборы и устройство для них
CN116888148A (zh) 追踪基因工程化细胞的肽标志物
HK40066864B (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof